Characteristic | Mean (SD) | Frequency n (%) |
---|---|---|
Age of primary diagnosis in years | ||
Mean | 52.3 (13.4) | |
Sex | ||
Male | 49 (48.5) | |
Female | 52 (51.5) | |
Primary Tumor Diagnosis | ||
Appendiceal | 48 (47.5) | |
Colorectal | 34 (33.7) | |
Gastric | 7 (6.9) | |
Ovarian | 3 (3.0) | |
Sarcoma | 3 (3.0) | |
Others | 6 (5.9) | |
Grade of primary tumor (n = 85) | ||
Grade 1 (Well differentiated) | 36 (42.9) | |
Grade 2 (Moderately differentiated) | 23 (27.4) | |
Grade 3 (Poorly differentiated/signet ring) | 25 (29.8) | |
Preoperative imaging | ||
Computed tomography (CT) scan | 89 (88.1) | |
Magnetic resonance imaging (MRI) scan | 41 (40.6) | |
Positron emission tomography (PET) scan | 62 (69.7) | |
Intraoperative PCI score (n = 74) | 15.5 (11.7) | |
HIPEC completed | 73 (72.3) | |
Completeness of cytoreduction (n = 65) | ||
CC0 | 52 (80.0) | |
CC1 | 9 (13.9) | |
CC2 | 4 (6.2) | |
Length of stay | 11.3 (9.1) | |
Grade 3 to 5 complications | 15 (20.5) | |
Chemotherapy received | 46 (45.5) | |
Before CRS | 16 (34.8) | |
After CRS | 19 (41.3) | |
Both before and after CRS | 11 (23.9) | |
Patients alive and under follow up | 82 (81.2) | |
Status at last office visit (n = 82) | ||
No disease | 31 (37.8) | |
Stable disease | 24 (29.3) | |
Progressive disease | 27 (32.9) |